[Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013139
German
Original Title:
Polatuzumab Vedotin (Kombination mit Rituximab, Cyclophosphamid, Doxorubicin und Prednison; bisher unbehandeltes DLBCL)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a24-60.html
Year Published:
2024
URL for published report:
https://www.iqwig.de/download/a24-60_polatuzumab-vedotin_addendum-zum-projekt-a23-141_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Antibodies, Monoclonal
- Immunoconjugates
- Antineoplastic Combined Chemotherapy Protocols
- Rituximab
- Cyclophosphamide
- Doxorubicin
- Prednisone
Keywords
- Polatuzumab Vedotin
- Lymphoma – Large B-Cell – Diffuse
- Benefit Assessment
- NCT03274492
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.